Sini San inhibits breast cancer cell migration and angiogenesis via the HIF 1 /VEGF pathway

Abstract

Purpose: To investigate the effects of Sini San (SNS) on breast cancer (BC), and the mechanism of action.Methods: MDA-MB-231 and SK-BR-3 cells were used as breast cancer cell models. Cell viability, migration, and invasion were determined by CCK-8, Transwell and wound healing assays, respectively. SNS mechanism of action and its anti-cancer effect were investigated by network pharmacological analysis, and further verified by Immunoblot.Results: Sini San inhibited the proliferation of the breast cancer (BC) cells., and also suppressed the migration as well as the invasion of BC cells, and also restrained the angiogenesis of BC cells. In performing the network pharmacological analysis of Sini Powder in the treatment of BC, 337 drugdisease targets were obtained. PPI network was established through String, and GO and KEGG enrichment analysis was performed on the target sites. KEGG analysis showed that genes were enriched in HIF-1 and VEGF pathways.Conclusion: Sini San suppressed cell migration as well as angiogenesis via the HIF-1 /VEGF pathway

Clinical Effect Observation of Apatinib Combined with 131I for Radioiodine-Refractory Differentiated Thyroid Cancer and Prognostic Significance Analysis of Macrophage Inflammatory Protein-1α After Treatment: A Cell Regulation Study

“…Among them, AP, a novel small molecule TKI drug, mainly acts on VEGFR-2 (Zhao et al, 2021). It is well known that VEGF and VEGFR play an important regulatory role in neovascularization, and the highly selective blockade of VEGFR-2 and its downstream signaling pathways by AP is utilized to inhibit the proliferation and migration of vascular endothelial cells to achieve tumor suppression (Zhang et al, 2022). Therefore, the combination of 131I through AP may effectively address the shortcomings of the current stage of 131I during the treatment of RAIR-DTC and provide more reliable prognosis for patients.…”